Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534706 | 0.81 | SLC6A3 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5523971 | 0.81 | ALDH1A1 (0.46) | CYP3A4CYP2C19LMNAEPHX2 | |
| SCHEMBL4600032 | 0.77 | EPHX1 (0.41) | CYP3A4EPHX1 | |
| SCHEMBL2864888 | 0.76 | MAOA (0.46) | SLC6A4SLC6A3SLC6A2LMNA | |
| SCHEMBL28780338 | 0.76 | SLC6A2 (0.42) | CYP3A4CYP2C9CYP2C19SLC6A4SLC6A3 | |
| SCHEMBL6244722 | 0.74 | MAOA (0.47) | SLC6A4SLC6A3SLC6A2LMNA | |
| SCHEMBL28009767 | 0.73 | ALDH1A1 (0.49) | CYP3A4CYP2C19LMNA | |
| SCHEMBL1826744 | 0.72 | AKT2 (0.53) | SLC6A4SLC6A3SLC6A2LMNAKCNH2 | |
| SCHEMBL1760955 | 0.71 | ALDH1A1 (0.46) | LMNA | |
| SCHEMBL5526973 | 0.71 | SLC6A4 (0.50) | CYP3A4CYP2C9CYP2C19SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | CYP3A4 334/4885CYP2C9 1280/4885CYP2C19 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.